Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
Do you reduce the dose of hydroxychloroquine in patients with skin graying if they are not particularly bothered by this side effect?
What specific historical questions do you prioritize when evaluating hair loss to identify features suggestive of autoimmune or connective tissue disorders?
In an infant whose mother resumes TNF inhibitor therapy (e.g., adalimumab, infliximab, certolizumab) after delivery and is breastfeeding, do you recommend delaying live vaccinations?
How do you manage recalcitrant tumid lupus in a patient with partial response to antimalarials and off-label apremilast, in the setting of coexisting MDS with significant neutropenia?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
